Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs-Reference-Cited by-同舟云学术

Treatment of Myelodysplastic Syndrome with Thrombomimetic Drugs

Published:2015-01 Issue:1 Volume:52 Page:38-45
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Santini Valeria,Fenaux Pierre

Publisher

Elsevier BV

Subject

Hematology

Reference43 articles.

1. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS);Malcovati;Haematologica,2011

4. Prognostic relevance of the kinetics of worsening of cytopenias in lower-risk MDS: a substudy from the European Leukemia Net Low Risk MDS (EUMDS) Registry;Itzykson;Blood,2012

5. A prognostic score for patients with lower risk myelodysplastic syndrome;Garcia-Manero;Leukemia,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Raising the bar for lower-risk myelodysplastic syndromes;Leukemia & Lymphoma;2023-04-08

2. Novel Strategies to Manage Cytopenia in Low-Risk MDS;Pathogenesis and Treatment of Leukemia;2023

3. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO;Leukemia;2022-09-07

4. Thrombocytopenia in myelodysplastic syndromes: time to lift the embargo on thrombomimetics?;British Journal of Haematology;2021-06-20

5. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients;eLife;2021-05-25